Geographic Atrophy

The purpose of this investigation was 2-fold: to estimate the costs of treating GA with pegcetacoplan and to identify possible utility measures to compare treatments for GA.

This compound will be evaluated for the treatment of geographic atrophy (GA). The company shared that the first-in-human study is set to commence in 2024.

According to the company, AVD-104 is an engineered glycan (sialic acid) nanoparticle designed to target the self-pattern recognition receptors on overly activated retinal immune cells, specifically macrophages and microglia.

These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients.

Phase 2/3 SIGLEC trial are underway. Data shared at EURETINA 2023 shows continued safety with no drug-related adverse events thus far in cohorts 1, 2, 3, and 4.

The use of silicone-free syringes advised with these drops.

Visual acuity changes and conversion to neovascular AMD determined over 3 years in large patient cohort.

The authors of a case series say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters.

G6501 is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

The company announced preliminary US net revenues of about $74 million for the injection, approved by the FDA earlier this year.

Kriya is developing a one-time gene therapy designed to block complement C3 and C5, which are clinically validated substrates targeted by FDA approved therapies, to delay the progression of geographic atrophy.

According to a news release, the J-code for SYFOVRE will become effective on October 1, 2023.

To educate patients on the disease, the company has enlisted the help of actor Eric Stonestreet and his mother, Jamey.

"Modern Family" actor and his mother, Jamey, are sharing their family’s story of GA and AMD to raise awareness of the disease.

According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.

Garg reported the 30-month data showing that patients receiving pegcetacoplan experienced an increasing treatment effect compared with sham (ie, a decrease in GA lesion area over time).

The podcast by Cognition Therapeutics features a discussion with retinal specialists.

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say!

According to the Keck School of Medicine of USC, the $12.4 million from the California Institute for Regenerative Medicine is the latest round of support for USC researcher Mark Humayun and a milestone in the development of a stem cell patch to treat advanced dry age-related macular degeneration.

According to the company, it is anticipating cost savings of up to $300 million through 2024, which includes an estimated 25% reduction in current workforce and a reduction in external expenses.

The company believes the 19-gauge filter needles may be the culprit in the SYFOVRE injections.

Astellas Pharma Inc. announced the European Medicines Agency (EMA) has accepted for regulatory review the marketing authorization application (MAA) for Iveric Bio’s avacincaptad pegol (ACP).

Carl Regillo, MD, FACS, FASRS, spoke with our team following the annual ASRS meeting in Seattle, Washington to share insights from his presentation titled, "Modulation of Macrophages and Complement Dysfunction in Non-exudative AMD utilizing novel, sialic-acid coated nanoparticles." Aviceda Therapeutics is unlocking the proteogenomic code of AMD to target proteins and pathways linked to macular degeneration.

According to the company, the solution slowed the loss of photoreceptors and disease progression as early as six months.

Paul Hahn, MD, PhD, shared insights on research comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy presented at the 2023 ASRS annual meeting.

Apellis Pharmaceuticals, Inc. presented results from the GALE extension study at the 2023 ASRS annual meeting in Seattle. The results indicated that continuous treatment with SYFOVRE (pegcetacoplan injection) for 30 months continued to show increasing beneficial effects.

Tarek Hassan, MD, spoke with our team about a novel glyco-mimetic nanoparticle, Aviceda AVD-104, being developed for the treatment of geographic atrophy.

At the 2023 ASRS annual meeting in Seattle, Washington, Ursula Schmidt-Erfurth, MD, spoke with our team to share information on the GALE extension study.

In presentations at the ASRS 41st Annual Meeting in Seattle, additional analyses support consistent protection from vision loss.

During presentations at the ASRS 41st Annual Meeting in Seattle, Apellis noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis, and no events were reported in clinical trials.